,10 for the ALWP of EBMT So far the impact of cytogenetics risk on outcome in the context of reduced intensity conditioning (RIC) allo-SCT has been poorly studied. We have identified 378 AML patients in first CR who underwent RIC allo-SCT from an HLA-matched sibling donor between 2000 and 2007 reported to the European Group for Bone and Marrow Transplantation and for whom detailed cytogenetics data were available (good risk: n ¼ 21; intermediate risk: n ¼ 304; and poor risk: n ¼ 53). With a median follow-up of 24 months (range: 1 --93), 2-year non-relapse mortality, relapse rate (RR), leukemia-free survival (LFS) and OS were 14%, 31%, 55% and 61%, respectively. Cytogenetics was significantly associated with RR (good risk: 10%; intermediate risk: 28%; and poor risk: 55% at 2 years, Po0.0001) and LFS (good risk: 64%; intermediate risk: 57%; and poor risk: 38% at 2 years, P ¼ 0.003). In a multivariate analysis, RR and LFS were significantly higher and lower, respectively, in the high-risk cytogenetics group (P ¼ 0.001, P ¼ 0.004) and in patients with a higher WBC at diagnosis (410 Â 10 9 /L) (Po0.001, P ¼ 0.004). As documented in the setting of myeloablative allo-SCT, patients with poor cytogenetics had increased RR and decreased LFS after RIC allo-SCT, requiring new prospective strategies to improve results in this subgroup.
INTRODUCTION
Allo-SCT is a well-established therapy for adult patients with AML. In the setting of the standard myeloablative allo-SCT, the fear of early death, as a result of the procedure, led to the restriction of allo-SCT in first CR to patients who presented with intermediate or high-risk AML features, especially taking into account the impact of cytogenetics risk on outcome determining standard good-, intermediate-and poor-risk populations. 1, 2 In the last decade, reduced intensity conditioning (RIC) allo-SCT has emerged as an attractive modality to decrease toxicity and widen the spectrum of AML patients who are candidate to allo-SCT. 3 However, the issue of possible higher relapse rates (RRs) for RIC allo-SCT and continuous improvements in non-allo-SCT strategies raise concern about the utility of this approach in AML patients in CR1 (for example, in comparison with intensive chemotherapy and new drugs). Of note, the impact of cytogenetics risk on outcome in the context of RIC allo-SCT has been poorly studied so far. 4, 5 
PATIENTS AND METHODS

Study design and data collection
This was a retrospective multicenter analysis. Data of adult AML patients receiving RIC allo-SCT were provided by the Acute Leukemia Working Party of the European Group for Bone and Marrow Transplantation (EBMT) group. EBMT registry is a voluntary working group of 4500 transplant centers, participants of which are required once a year to report all consecutive SCTs and follow-up. The Acute Leukemia Working Party of the EBMT group approved this study, which was performed according to the EBMT guidelines.
This report describes the results of 378 non-M3 AML patients transplanted in CR1 using a RIC regimen and reported to the EBMT registry between 2000 and 2007, and for whom detailed cytogenetics data were available. Karyotypic abnormalities were classified as favorable if t(8;21) or inv(16)/t(16;16) were present, high risk if abn(3q) (excluding t(3;5)), inv(3)/t(3;3), add(5q)/del(5q), À5, À7, add(7q)/del(7q), t(6;11), t(10;11), other t(11q23) (excluding t(9;11) and t(11;19), t(9;22), À17, abn (17p) or multiple abnormalities (more than three) were observed and intermediate in all other cases, including normal karyotypes. 6 
Patients and transplant procedures
Patients, disease and transplant characteristics are summarized in Table 1 . There were 185 males and 193 females with a median age of 55 (range, 18 --74) years at the time of allo-SCT. All patients received RIC allo-SCT from an HLA-identical sibling. RIC was defined as BU conditioning regimens containing o8 mg/kg total dose or TBI o6 Gy. 7 The reasons for receiving RIC regimen were mainly age 450 years, presence of one or several significant co-morbidities precluding the use of a standard myeloablative conditioning regimen or per protocol design. The median intervals from AML diagnosis to CR1 and from CR1 to RIC allo-SCT were 45 and 155 days, respectively. GVHD prophylaxis consisted of CsA alone, CsA þ MTX, CsA þ mycophenolate mofetyl or alemtuzumab in 103, 106, 88 and 62 patients, respectively (unknown n ¼ 19). In this series, 21 patients (6%) belonged to the good cytogenetics risk group, whereas 304 patients (80%) and 53 patients (14%) belonged to the intermediate and poor cytogenetics risk groups, respectively. The reasons for RIC allo-SCT for patients belonging to the good cytogenetics risk were CR achievement after two inductions in 12, hyperleukocytosis in 2 and unknown in 7. Age, year of transplant, WBC at diagnosis, gender, CMV serostatus, stem cell source and RIC regimen type were comparable between all the three groups. The M5-6-7 FAB subgroup was significantly higher in the poor-risk group (30% vs 20% in the intermediate group, P ¼ 0.01). The median interval between diagnosis and CR1 was significantly lower in the good-risk group (P ¼ 0.04).
Statistical analysis
Clinical outcomes that were studied were 2-year overall survival (OS), leukemia-free survival (LFS), RR and non-relapse mortality (NRM). Acute GVHD (aGVHD) and chronic GVHD (cGVHD) was diagnosed and graded at each transplant center according to the standard criteria. 8, 9 Characteristics considered were recipient age at transplant, recipient and donor sex, recipient and donor CMV status, disease features (WBC at diagnosis, AML FAB subtype, cytogenetics and interval between diagnosis and CR1) and allo-SCT characteristics (year of transplant, interval between diagnosis and transplant, GVHD prophylaxis (Anti-thymoglobulin (ATG): yes or no), conditioning regiment (TBI: yes or no) and stem cell source (BM vs PBSCs). LFS was defined as survival without evidence of relapse or progression. Relapse was defined as any event related to the recurrence of the disease. NRM was defined as death from any cause without previous relapse or progression. Starting on day 1, aGVHD was scored according to the standard criteria and counted only for grades XII. Patients surviving 4100 days after transplant with sustained donor hematopoiesis were considered at risk for the development of cGVHD. Cumulative incidence curves were used for RR and NRM in a competing risks setting. 10 For estimation of GVHD, death was considered as a competing event. Probabilities of LFS were calculated using the Kaplan --Meier method. The log-rank test was used for univariate comparisons. For all prognostic analyses, the median value of continuous variables was used as a cut-off point. Factors associated with a P-value o0.10 by univariate analysis were included in the final model. Associations of patient and graft characteristics with outcomes were evaluated in multivariate analyses using Cox proportional hazards. All the tests are two-sided. The type I error rate was fixed at 0.05 for determination of factors associated with time to event outcomes. Statistical analyses were performed with the SPSS (SPSS, Inc., Chicago, IL, USA) and Splus (MathSoft, Inc., Seattle, WA, USA) software packages.
RESULTS
The patients analyzed here were representative of the entire population who had RIC allograft during the same period. When comparing our cohort study with available cytogenetic information with the groups of patients fitting the same inclusion criteria and transplanted during the same period, with missing information regarding cytogenetics, we could show that both groups shared similar outcome (2-year OS: 61±3% vs 58±3%, P ¼ 0.29; 2-year LFS: 55 ± 3% vs 47 ± 3%, P ¼ 0.11).
Engraftment was observed in 365 patients (96.5%). The median time for neutrophil recovery was 15 days (range: 1 --43). aGVHD grade X2 was observed in 97 of 367 evaluable patients (26%). Cumulative incidences of aGVHD grade X2 according to the cytogenetics were as follows: good risk: 18 ± 10%, n ¼ 21; intermediate risk: 26±3%, n ¼ 294; and poor risk: 14±5%, n ¼ 52, P ¼ 0.25. Considering patients alive at day 100 and 8) . Cumulative incidences of 2-year cGVHD according to the cytogenetics were as follows: good risk: 81±11%, n ¼ 18; intermediate risk: 50±3%, n ¼ 244; and poor risk: 49 ± 8%, n ¼ 44, P ¼ 0.14.
With a median follow-up of 24 (range, 1 --93) months for survivors, the 2-year OS and LFS were 61±3% and 55±3%, respectively. The 2-year OS according to the cytogenetics were as follows: good risk: 69 ± 11% (Figure 1) . In univariate and multivariate analyses (Tables 2 and 3) , LFS was significantly influenced by the cytogenetics risk groups (P ¼ 0.003, P ¼ 0.004), the WBC at diagnosis (p or 410 Â 10 9 /L) (P ¼ 0.02, P ¼ 0.004). Acute and cGVHD did not affect LFS (P ¼ 0.27; P ¼ 0.3) significantly.
Overall, the 2-year RR was 31±3%. The 2-year RR according to the cytogenetics risk groups were as follows: good risk: 10 ± 6%, n ¼ 21; intermediate risk: 28 ± 3%, n ¼ 304; and poor risk: 55 ± 7%, n ¼ 53, Po0.0001 (Figure 2) . In a multivariate analysis (Table 3) , cytogenetics (P ¼ 0.001), WBC at diagnosis (p or 410 Â 10 9 /L) (Po0.001) and the use of ATG (P ¼ 0.005) were the three independent factors associated with RR in this cohort. Also, aGVHD grade II --IV and cGVHD were associated with a lower risk of relapse (HR ¼ 0.46; 95% CI: 0.24 --0.89; P ¼ 0.02 and HR: 0.5; 95%CI: 0.27 --0.96; P ¼ 0.04).
Overall, the 2-year NRM was 14±2%. The 2-year NRM according to the cytogenetics were as follows: good risk: 27±11%, n ¼ 21; intermediate risk: 15 ± 2%, n ¼ 304; and poor risk: 8 ± 4%, n ¼ 53, P ¼ 0.21 ( Figure 3) . In a multivariate analysis (Table 3) , the risk of mortality was statistically significantly higher for patients grafted after 2004 (P ¼ 0.02), whereas cytogenetics was not significantly associated with NRM. Also, conversely to cGVHD (P ¼ 0.21), aGVHD grade II --IV was associated with a higher NRM (HR: 4.7; 95% CI: 2.58 --8.58; Po0.001).
DISCUSSION
Our study is one of the largest studies reporting specifically the outcomes of a cohort of AML patients in CR1 according to the cytogenetics subgroups in the setting of RIC allo-SCT. As previously shown in the standard myeloablative setting, we could show that the relapse risk and LFS were significantly influenced by the cytogenetics risk groups.
Cytogenetics is the main prognostic factor for outcomes in the setting of AML, both in young and old patients.
1,2,6,11 --13 Despite the advent of new molecular classifications, 2 the use of the three risk groups (good, intermediate and high-risk groups) is still widely used for guiding patients' therapy.
Currently, myeloablative allogeneic transplantation is the standard of care for AML patients under the age of 50 --55 years in CR1 with intermediate (excluding those patients with normal karyotype and being NPM1 þ /FLT3ÀITDÀ or biallelic CEBPalpha þ /FLT3ÀITDÀ) or poor-risk cytogenetics. 2, 14 The use of a matched unrelated donor is recommended, at least in highrisk or FLT3ÀITD þ patients, as it seems to provide similar outcomes compared with the use of a sibling donor. 15, 16 However, the benefit of the standard allo-SCT may be offset by the high rate of NRM. With this background, RIC allo-SCT is increasingly considered for those older AML patients or patients with comorbidities who cannot receive a standard myeloablative conditioning. Nevertheless, the role of RIC all-SCT in older patients remains contentious and there is no consensus about its routine use. Indeed, a controlled prospective comparison between the standard and RIC allo-SCT in AML is not yet available, 17 despite some reports showing similar outcomes, with the higher rate of relapse after RIC being counterbalanced by the higher rate of NRM after the standard conditioning. 4, 18 One of the largest series of RIC allo-SCT for AML was reported by Gyurkocza et al. 5 in 274 patients with various status at transplant (CR1, CR2 and advanced /refractory) who received lowdose TBI with or without Fludarabine. In this series, the 5-year DFS and OS rates were 32% and 33%, respectively. Results of the current analysis confirm the Gyorkocza results and appear RIC geno-identical allo-SCT in AML patients in CR1 P Chevallier et al superior. Nevertheless, this is hardly surprising given that all of our patients were in CR1. It is well accepted that older AML patients (who are likely to be candidates for RIC allo-SCT) 19 exhibit higher therapeutic resistance due to higher adverse cytogenetics, secondary AML or MDR phenotype. 2 Thus, age per se is considered as a poor prognostic factor of outcome and OS did not exceed 30% at 3 years in different series. 11 --13 However, cytogenetics also remain as an independent prognostic factor in older AML patients, and patients belonging to the good-risk group have higher chance of survival but, however, lesser from what is observed in younger patients. 11, 13, 20 Our study not only confirms the relatively good results of RIC-allo SCT in AML patients in CR1 4, 5, 17, 18 but also provides some data on the potential benefit of RIC allo-SCT according to the cytogenetics, as a 2 --3-year LFS of around 60% is obtained for patients in the intermediate subgroup. Nevertheless, prospective studies are needed to confirm the superiority of RIC allo-SCT compared with non-transplant treatment strategies in AML.
For patients with high-risk cytogenetics, LFS is still unsatisfactory after RIC allo-SCT and new strategies are needed to improve outcomes.
Recent years were associated with higher NRM (see Table 3 ). There is no clear explanation for that, but there was a trend for higher median age in patients transplanted after 2004 (56 vs 54.55 years, P ¼ 0.09). Also, out of the 131 patients for whom the presence or not of at least one co-morbidity condition was reported, it was present in 46 out of 84 transplanted before 2004 (55%) and 29 out of 47 after 2004 (62%).
In conclusion, despite its retrospective nature, results from this large study strongly suggest that RIC allo-SCT from an HLAmatched sibling donor is a valid option for AML patients in CR1 not eligible for the standard allo-SCT. As it has been shown in the setting of myeloablative conditioning allo-SCT, the classical AML cytogenetics risk classification retains its prognostic value after RIC allo-SCT. Patients from the poor cytogenetics risk group had increased relapse incidence and decreased LFS rate after RIC allo-SCT. Therefore, prospective strategies, such as the use of novel drugs for conditioning regimen (for example Clofarabine) 21 or post HST immune interventions, 22 should be investigated to improve current results. 
